Medtronic stock gains as CMS proposes coverage for renal denervation

Medtronic (MDT) stock gained following a proposed Centers for Medicare and Medicaid Services (CMS) decision to cover Renal Denervation (RDN) procedures, including Medtronic's therapy, with a final decision expected by October 2025. This regulatory milestone presents a significant market opportunity, potentially transforming Medtronic's Coronary and Peripheral Vascular division's growth trajectory. While analysts broadly view the development as positive, projecting hundreds of millions in new revenue by FY2029, some caution that specific coverage criteria and patient workflow requirements may lead to a more gradual revenue contribution.

Analysis

Medtronic (MDT) has received a significant regulatory tailwind with the Centers for Medicare and Medicaid Services (CMS) issuing a proposed Decision Memo to cover Renal Denervation (RDN) procedures. This development, which positively impacted the stock already up 18% over the past year, is a critical step towards unlocking a market potentially worth tens of billions for its RDN technology targeting uncontrolled hypertension. Analyst projections for the financial impact are substantial, with Goldman Sachs estimating $250-300 million in revenue contribution by fiscal year 2029, and BofA Securities forecasting $100-150 million in annual growth. This is expected to pivot Medtronic's Coronary and Peripheral Vascular division from low-single-digit declines to mid-single-digit growth. However, the optimism is tempered by cautious outlooks from several firms. Goldman Sachs, while acknowledging the news as "objectively positive," maintains a Sell rating and a $78.00 price target, citing that patient workflow and specific facility requirements detailed in the proposal will likely lead to a gradual revenue ramp-up. This sentiment is echoed by BTIG and reflected in the Neutral and Market Perform ratings from JPMorgan and William Blair, respectively. The final coverage decision, due by October 8, 2025, remains the key catalyst that will determine the ultimate pace of adoption and financial returns.

Key Decisions for Investors

• The proposed CMS coverage is a major de-risking event for Medtronic's long-term RDN growth story, warranting consideration for investors with a multi-year horizon focused on the medical technology sector.
• Investors should moderate near-term expectations, as the consensus among several analysts suggests revenue contribution will be gradual due to specific patient and facility requirements, which may not be fully priced into a stock trading near its 52-week high.
• The final CMS decision by October 8, 2025, is the most critical upcoming catalyst; its final terms will dictate the true market size and adoption rate, making it a key event to monitor before significantly adjusting positions.
• Given the starkly mixed analyst ratings, from Buy to Sell, investors should scrutinize the differing assumptions regarding the pace of RDN adoption to inform their own thesis on the company's growth trajectory versus its current valuation.